Publication for MAGEA1 and CTAG2

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	MAGEA1	MAGE family member A1	4100			[link]
hsa	CTAG2	cancer/testis antigen 2	30848

Pubmed ID	Priority	Text
23680437	0.98	MAGE-A1 specific mAb 77B (A.), or multi-MAGE-A specific mAb 57B (B.) or with NY-ESO-1/LAGE-1 specific mAb D8.38 (C.).
	0.97	MAGE-A1 was infrequently detectable in DLBCL specimens (12.50%), whereas multi-MAGE-A and NY-ESO-1/LAGE-1 specific reagents stained the cytoplasms of tumor cells in DLBCL specimens with higher frequencies (54.17% and 37.50%, respectively) with different expression levels.
	0.96	LAGE-1 and negative for MAGE-A1 expression.
	0.86	MAGE-A1 or NY-ESO-1/LAGE-1 expression, whereas the SLL was negative for all CTA under investigation.
	0.75	MAGE-A1, 57B recognizing an epitope shared by multiple MAGE-A CTA (multi-MAGE-A specific) and D8.38 recognizing NY-ESO-1/LAGE-1 were used for immunohistochemical staining of 27 PTL, including 24 DLBCL.
22294213	0.98	MAGE-1, MAGE-3, MAGE-4, MAGE-10, CT-7, NY-TLU57, NY-ESO-1, and LAGE-1) in lung cancer tissues.
	0.84	MAGE-1, MAGE-3, MAGE-4, MAGE-10, CT-7, NY-TLU-57, NY-ESO-1 and LAGE-1) was assessed by RT-PCR in 79 lung cancer tissue samples.
	0.84	MAGE-1 (21/79, 27%), CT-7 (16/79, 20%), MAGE-4 (15/79, 19%), LAGE-1 (13/79, 16%), MAGE-10 (11/79, 14%), SSX-2 (3/79, 4%), SSX-4 (2/79, 3%), NY-TLU-57 (1/79, 1%), SCP-1 (0/79, 0%) and SSX-1 (0/79, 0%) (Fig. 2).
	0.66	MAGE-1 (27%), CT-7 (20%), MAGE-4 (19%), LAGE-1 (16%), and MAGE-10 (14%).
24457462	0.98	MAGEA1, MAGEA3, NY-ESO-1, LAGE-1, and SSX2 are all immunogenic cancer-testis-X antigens that have been shown to elicit coordinated humoral and cell-mediated immune responses.
	0.96	MAGEA1, ACRBP, PRAME, and SSX2 by immunohistochemistry and PRAME, CTAG2, and MAGEA3 by quantitative real-time PCR.
27294163	0.98	MAGEA1, CTAG1, CTAG2, SSX1, and SSX4 in patients with improved survival.
	0.96	CTAG2, MAGEA1, SSX1, and SSX4 are circled in a cluster.
17650306	0.98	CTAG2, CAGE1, MAGEA1, MAGEA4 and MAGEA11.
16255778	0.97	CTAG2, a colon cancer antigen 16, and MAGEA1) were elevated in the clone that did not metastasize.
23145101	0.97	CTAG2, MAGEA12, MAGEA1, MAGEA3, MAGEA6, MAGEC1, MAGEC2, and PTTG1) and transcripts important in regulating development (HOXB7, HOXB8, HOXB9, NANOGNB, and LOC404266).
28555838	0.97	MAGE-A1, MAGE-A3, MAGE-A4 and/or NY-ESO-1/LAGE-1 (Table 1).
28849093	0.96	MAGEA1, 25.5% (13/51); NY-ESO-1, 19.6% (10/51); PLAC1, 19.6% (10/51); LAGE1, 17.6% (9/51); MAGEC2, 7.8% (4/51); SPANXC, 7.8% (4/51); SPANXA1, 2.0% (1/51); and FATE1, 0% (0/51).
	0.94	L antigen 1 (LAGE1), MAGEA1, MAGEA3, NY-ESO-1, sperm protein associated with the nucleus on the X chromosome (SPANX) A1, SPANXC and synovial sarcoma X breakpoint 1 (SSX1).
	0.89	MAGEA1, NY-ESO-1, PLAC1 and LAGE1) demonstrated high positive rates in the PBMCs of patients with HCC and were selected for further analysis.
	0.87	MAGEA1, 1/102.5-1/106.5; NY-ESO-1, 1/103.5-1/106; PLAC1, 1/104-1/105.5; and LAGE1, 1/102-1/105.5.
27769045	0.88	MAGE-A1, MAGE-A2, MAGE-A8, MAGE-B1, GAGE-2, NY-ESO1, NY-SAR35, NXF-2, XAGE-1 and SPANXC), and twelve were undetectable in all cell lines tested (MAGE-E1, GAGE-4, GAGE-7, PAGE-1, LAGE-1, SSX5, FATE-1, TPX-1, MAD-CT1, MAD-CT2, ADAM2 and TSP50).
24772169	0.83	MAGE-A1 in 10.8% of carcinoma samples, whereas multi-MAGE-A and NY-ESO-1/LAGE-1 stained 85.9% and 84.8% of samples using immunohistochemistry, suggesting that a panel of CT antigens rather than individual ones may be more valuable as biomarkers.
26504497	0.69	MAGEA1, MAGEA3, CTCFL, CTAG2, SSX1, and NXF2) were analyzed by RT-qPCR.